ArticleJournal of inflammation research2026
Intracellular ATP Levels in CD4
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the prognostic significance of CD4⁺ T-cell intracellular adenosine triphosphate (iATP)-derived parameters in adult ICU patients with sepsis, and to explore whether integrating stimulated iATP (s-iATP) with the APACHE II score provides additional prognostic information for 28-day mortality prediction. Methods: This single-center retrospective cohort study included adult ICU patients with sepsis admitted between May 2022 and March 2024. CD4⁺ T-cell iATP parameters, including s-iATP, non-stimulated iATP (n-iATP), the difference (s-n iATP), and the ratio (s/n iATP), were measured within 24 hours of sepsis diagnosis. Associations between iATP parameters and clinical outcomes, particularly 28-day mortality, were evaluated using survival and predictive analyses, and the prognostic value of combining s-iATP with the APACHE II score was assessed. Results: A total of 131 patients were divided into high (n = 99) and low (n = 32) s-iATP groups based on the optimal cutoff value of 68 ng/mL. s-iATP showed a weak positive correlation with CD4⁺ T-cell count (r = 0.24). ROC analysis identified s-iATP as the best predictor of 28-day mortality (AUC = 0.760). Patients in the low s-iATP group had higher 28-day mortality, in-hospital mortality, progression to septic shock, and development of MODS among those without MODS at admission. After adjustment for confounders, low s-iATP remained independently associated with increased 28-day mortality (HR = 2.53, 95% CI: 1.12-5.74, Conclusion: Low s-iATP levels within 24 hours of sepsis diagnosis were independently associated with increased 28-day mortality in adult ICU patients with sepsis. s-iATP may provide functional immune information complementary to conventional severity scores, but its incremental prognostic value requires further validation in larger prospective cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.